gms | German Medical Science

Infektiologie Update 2016: 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)

Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)

06.-08.10.2016, Rostock

Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation

Meeting Abstract

  • Guido A. Gualdoni - Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
  • Tilman Lingscheid - Department of Infectious Diseases and Pulmonary Medicine, Charité – Universitätsmedizin Berlin, Germany
  • Klaus G. Schmetterer - Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  • Annika Hennig - Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
  • Peter Steinberger - Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
  • Gerhard J. Zlabinger - Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria

Infektiologie Update 2016. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). Rostock, 06.-08.10.2016. Düsseldorf: German Medical Science GMS Publishing House; 2016. Doc16peg18

doi: 10.3205/16peg18, urn:nbn:de:0183-16peg187

Veröffentlicht: 30. September 2016

© 2016 Gualdoni et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Deregulation of inflammasome activation was recently identified to be involved in the pathogenesis of various inflammatory diseases. Although macrolide antibiotics display well described immunomodulatory properties, presumably involved in their clinical effects, their impact on inflammasome activation has not been investigated. We compared the influence of macrolides on cytokine induction in human monocytes. The role of intracellular azithromycin-accumulation was examined by interference with Ca++-dependent uptake. We have also analysed the signalling cascades involved in inflammasome activation, and substantiated the findings in a murine sepsis model. Azithromycin, but not clarithromycin or roxithromycin, specifically inhibited IL-1α and IL-1β secretion upon LPS stimulation. Interference with Ca++-dependent uptake abolished the cytokine-modulatory effect, suggesting a role of intracellular azithromycin accumulation in the modulatory role of this macrolide. Azithromycin’s inhibiting effects were observed upon LPS, but not upon flagellin, stimulation. Consistent with this observation, we found impaired induction of the LPS-sensing caspase-4 whereas NF-κB signalling was unaffected. Furthermore, azithromycin specifically affected IL-1β levels in a murine endotoxin sepsis model. We provide the first evidence of a differential impact of macrolides on the inflammasome/IL-1β axis, which may be of relevance in inflammasome-driven diseases such as chronic obstructive pulmonary disease or asthma.

Figure 1 [Fig. 1]